摘要
目的分析术前血清过氧化还原酶1(PRDX1)、PTEN水平对肝细胞癌患者经肝动脉插管化疗栓塞术(TACE)治疗预后的评估价值。方法选取接受TACE治疗的肝细胞癌患者73例,按照其外周血PRDX1、PTEN水平,分为高PRDX1组、低PRDX1组,或者分为高PTEN组、低PTEN组。比较各组临床病理特征和预后生存情况,采用多因素回归分析预后的影响因素,采用ROC曲线评估PRDX1、PTEN对预后的预测价值。结果年龄>55岁、肿瘤大小>5 cm、肿瘤数目>3个、病理分期T2~T4期、门静脉侵犯者比例均高PRDX1组高于低PRDX1组,低PTEN组高于高PTEN组(P<0.05)。低PRDX1组3年生存率高于高PRDX1组,高PTEN组高于低PTEN组(P<0.05)。病理分期T2~T4期、门静脉侵犯、高PRDX1、低PTEN均是影响肝细胞癌患者TACE治疗预后的危险因素(P<0.05)。ROC曲线分析发现,PRDX1、PTEN对肝细胞癌患者TACE治疗预后具有一定评估价值(P<0.05)。结论肝细胞癌患者术前血清PRDX1、PTEN水平可评估其TACE治疗预后。
Aim To evaluate the values of preoperative serum levels of peroxidase REDOX proteinase-1(PRDX1)and PTEN on prognosis of patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization(TACE).Methods 73 patients with hepatocellular carcinoma receiving TACE were selected.According to the levels of PRDX1 and PTEN in peripheral blood,they were divided into high PRDX1 group and low PRDX1 group,or high PTEN group and low PTEN group.The clinicopathological features and prognosis survival of each group were compared,and the influencing factors of prognosis were analyzed by multi-factor regression.The predictive value of PRDX1 and PTEN for prognosis was evaluated by ROC curve.Results With the proportion of age>55,tumor size>5 cm,number of tumors>3,and pathological stage T2~T4,portal vein invasion were higher in the high PRDX1 group than that in the low PRDX1 group,and higher in the low PTEN group than that in the high PTEN group(P<0.05).The 3-year survival rate of low PRDX1 group was higher than that of high PRDX1 group,and higher in high PTEN group compared with low PTEN group(P<0.05).Pathological stage T2~T4,portal vein invasion,high PRDX1 and low PTEN were all risk factors for the prognosis of hepatocellular carcinoma patients treated with TACE(P<0.05).ROC curve analysis showed that PRDX1 and PTEN had a certain value in evaluating the prognosis of patients with hepatocellular carcinoma treated with TACE(P<0.05).Conclusion Preoperative serum PRDX1 and PTEN levels can evaluate the prognosis of patients with hepatocellular carcinoma treated with TACE.
作者
周立芳
张欣
张重阳
王宇
张家驹
王云霞
隋永博
ZHOU Lifang;ZHANG Xin;ZHANG Chongyang;WANG Yu;ZHANG Jiaju;WANG Yunxia;SUI Yongbo(Hepatobiliary Surgery Department 1st,Cangzhou Integrated Traditional Chinese and Western Medicine Hospital of Hebei,Cangzhou 061000,Hebei,China;Anesthesiology Department of Eastern Hospital,Cangzhou Integrated Traditional Chinese and Western Medicine Hospital of Hebei,Cangzhou 061000,Hebei,China)
出处
《中南医学科学杂志》
2025年第1期96-98,161,共4页
Medical Science Journal of Central South China
基金
河北省卫生健康委医学科学研究课题(20232146)。
